Clinical Trials Directory

Trials / Completed

CompletedNCT02580474

The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
21 (actual)
Sponsor
Myeong Jun Song · Academic / Other
Sex
All
Age
19 Years
Healthy volunteers
Not accepted

Summary

Safety and Efficacy of DAAs (Daclatasvir+Asunaprevir) in patients with chronic hepatitis C and chronic renal failure will be assessed.

Conditions

Interventions

TypeNameDescription
DRUGDaclatasvir plus Asunaprevir

Timeline

Start date
2016-02-01
Primary completion
2018-04-01
Completion
2018-04-01
First posted
2015-10-20
Last updated
2018-07-18

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT02580474. Inclusion in this directory is not an endorsement.

The Safety and Efficacy of Daclatasvir and Asunaprevir With Chronic HCV Genotype 1b Infection and Chronic Renal Failure (NCT02580474) · Clinical Trials Directory